MEI Pharma, Inc.
NASDAQ: MEIP0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Justin J. File CPA
- Employees
- 28
- Headquarters
- San Diego, United States
- IPO year
- 2003
- Market cap
- $20.5M
- Website
- https://www.meipharma.com
Loading MEIP…
Loading profile data…Frequently asked questions about MEIP
What does MEI Pharma, Inc. (MEIP) do?
MEI Pharma, Inc. is a late-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for various cancers. Its robust pipeline features several key assets: Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor, is currently in a Phase III clinical trial for relapsed/refracto...
Where does MEIP trade?
MEI Pharma, Inc. (MEIP) trades on the NASDAQ Capital Market.
What sector is MEIP in?
MEI Pharma, Inc. (MEIP) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of MEI Pharma, Inc.?
Justin J. File CPA is the chief executive officer of MEI Pharma, Inc. (MEIP).
Where is MEI Pharma, Inc. headquartered?
MEI Pharma, Inc. is headquartered in United States.
Does MEIP pay a dividend?
MEI Pharma, Inc. (MEIP) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MEIP go public?
MEI Pharma, Inc. (MEIP) completed its initial public offering in 2003.